Brian Gladsden, former head of Novartis Oncology, has been appointed chief executive of Mosaic Therapeutics Ltd, an oncology spin-out of the Wellcome Sanger Institute in the UK. Mosaic is extracting information from large datasets in order to identify and develop therapies for patients with specific genetic profiles. At Novartis, Mr Gladsden was responsible for global commercialisation and strategy for the company’s oncology portfolio. Prior to this, he worked in sales and marketing at Bayer AG.
Mr Gladsden holds a master’s degree in international business studies from the University of South Carolina, US.
Mosaic announced the appointment on 4 April 2023.
Copyright 2023 Evernow Publishing Ltd